Effectiveness and safety assessment of beta-blockers, calcium channel blockers, and angiotensin receptor blockers in hypertensive patients: a prospective study.

Nilay Solanki, Dhruvi Pandit, Shubha Desai

Open access · greenAbstract read

In one paragraph

Article in American journal of cardiovascular disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed, 1 pooled it

0.8field-weighted citation impact, top 25% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

Can Posterior Pericardial Incision Truly Improve Postoperative Complications After Cardiac Surgery? A Systematic Review and Meta-Analysis.Brazilian journal of cardiovascular surgery · 2023
Pooled it
Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.BMC medicine · 2025
Trial
Comparative maternal-fetal outcomes associated with different antihypertensive treatment strategies in preeclampsia: a retrospective cohort study.Frontiers in pharmacology · 2026
Article
Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions.Journal of evaluation in clinical practice · 2025
Review
Prevalence of inpatient blood pressure elevations in Australian hospitalised patients and analysis of associated factors.Internal medicine journal · 2025
Article
Assessment of antibacterial drug utilization patterns and antibiogram in infectious diseases: a prospective cross-sectional study.Naunyn-Schmiedeberg's archives of pharmacology · 2024
Observational
Sexual Dimorphic Interplays Between Gut Microbiota and Antihypertensive Drugs.Current hypertension reports · 2023
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nilay SolankiDepartment of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus Changa 388421, Gujarat, India.

Dhruvi PanditDepartment of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus Changa 388421, Gujarat, India.

Shubha DesaiResearch Department, Dr. Jivraj Mehta Smarak and Health Foundation Ahmedabad, Gujarat, India.

Charotar University of Science and Technology · INGujarat Kidney Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension is most common prevailing cardiovascular disease worldwide. In this condition the effectiveness and safety of already available and many time-tested medications should be regularly reviewed. METHODOLOGY: Ethical approval of study was obtained from human research ethics committee of the hospital. 180 patients were enrolled with three groups of antihypertensive medication groups as calcium channel blocker (amlodipine), beta blocker (metoprolol) and angiotensin receptor blocker (telmisartan) over a span of eight months. The data was obtained from week zero to twelve (SBP: Systolic Blood Pressure and DBP: Diastolic Blood Pressure). Safety of Beta blocker, calcium channel blocker and angiotensin receptor blocker were investigated.

resultsComparison of efficacy between the beta blocker, calcium channel blocker and angiotensin blocker receptor blocker were shown to be non-significant. It indicated that all drug therapies have the same successful reduction of SBP (P-0.4819). No significant adverse reactions were observed in either class of the medicines.

conclusionThe study showed the efficacy of Calcium Channel Blocker, Beta Blocker and Angiotensin Receptor Blocker in reduction of SBP & DBP was same, while Calcium Channel Blockers were superior to other two medications.

Indexed as

angiotensin receptor blockerbeta blockerCalcium channel blockerefficacysafety

Identifiers

PMID34849291

PMCPMC8611269

OpenAlexW3215194844

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.